TSXV:LBL.H - Post by User
Post by
laroplexon Oct 12, 2016 9:10am
101 Views
Post# 25334050
Fighting the Growing Osteoarthritis (OA) Problem
Fighting the Growing Osteoarthritis (OA) Problem
Fighting the Growing Osteoarthritis (OA) Problem
|
Approximately 27 million Americans are affected
- OA is the most common joint disorder in the US.
- ~10% of men and 13% of women 60 and older suffer from OA of the knee.
- OA is the most common reason for both total hip and total knee replacement.
- OA can affect any joint, but it occurs most often in knees, hips, lower back and neck, small joints of the fingers and the bases of the thumb and big toe.
- The number of people affected with OA is only expected to increase due to the aging of the population and the obesity epidemic.
- This already common disease is increasing rapidly - its impacts on public wellness and healthcare costs is only expected to snowball into the future.
The standard osteoarthritis therapies available to patients (such as oral therapies, intra-articular joint injections, and synthetic hyaluronic acid (HA) viscosupplements) offer inadequate relief, pose many serious side effects, or have not demonstrated proven results.
|
Introducing AmnioVisc™ - Proven Amnio Viscosupplement for Osteoarthritis
|
AmnioVisc™ Delivers Meaningful Results
Lattice Biologics is excited to launch an amnio viscosupplement for all joints. AmnioVisc™ is a 100% natural, minimally processed amniotic fluid supplement for the treatment of joint pain associated with OA. In what is the largest study ever conducted on an amnio viscosupplement, AmnioVisc™ clearly outperformed the traditional standard of care HA-based viscosupplementation products.
AmnioVisc™was shown to reduce pain, stiffness and difficulty at statistically significant levels for patients with knee osteoarthritis in a protocol-driven, WIRB controlled Registry of 275 patients documented so far in this protocol-driven study.
- At 30 days, 75% reported pain relief that was greater than 40%.
- At 90 days, the number of patients reporting greater than 40% relief increased to nearly 80%.
- At 180 days (six months), two thirds of the patients (67%) were still reporting greater than 40% pain relief.
|
|
(see the AmnioVisc™ press release)
|
|
The AmnioVisc™ Advantage
Amniotic fluid is likely more effective as a viscosupplement than either rooster comb derived HA or HA produced by fermentation technique for several reasons:
1. It is 100% human.
Hyaluronan from human amniotic fluid is immune privileged (it lacks MHC antigens so it does not elicit an inflammatory immune response).
2. The components of amniotic fluid are very similar to healthy, native human synovial fluid.
Amniotic fluid and synovial fluid are ultrafiltrates from blood plasma and contain hyaluronan as well as phospholipids, cholesterol, growth factor proteins, cytokines and nearly the same inorganic compounds.
3.It restores correct pH levels.
Human amniotic fluid has a pH level of about 7.0; the same as healthy synovial fluid. Osteoarthritis creates an acidic, toxic environment that causes pH levels to fall, typically, to about 3.5. Human amniotic viscosupplementation restores healthy pH levels, allowing the patient's own synovium to recover and --potentially-- slow or even halt progression of the disease.
|
To order, email:
For more information, call:
1-855-286-8088 (toll-free)
|